CA-MULTEFIRE-ALLIANCE
19.11.2020 15:02:06 CET | Business Wire | Press release
The MulteFire Alliance (MFA) today announced the launch of its MulteFire 1.0 Certification Program. In addition, the first customer premise equipment (CPE) device has been certified compliant.
With MulteFire technology, organizations can now cost-effectively deploy their own private LTE network and realize the benefits of better capacity, coverage, mobility and built-in security needed for industry 4.0 use cases.
The MulteFire 1.0 specification defines LTE operation in unlicensed and shared spectrum bands, including the global 5 GHz band. The certification program tests eNodeBs together with UEs for conformance with the MulteFire 1.0 specification to ensure an interoperable, global device ecosystem for use in unlicensed or shared radio spectrum. By removing the need for licensed spectrum, MulteFire will help to lower entry cost and accelerate high-speed, secure private wireless networking deployment.
MulteFire technology opens up an entirely new range of private wireless use cases that add to existing deployment scenarios in asset-intensive industries. New opportunities include rapid deployment situations such as field hospitals and emergency response, as well as temporary systems for pop-up events, touring, cultural and sports programs. In addition, MulteFire can also be used to complement existing private wireless deployment in licensed spectrum, for example to add capacity by tapping into the large bandwidth available in the unlicensed 5 GHz spectrum band.
“The MulteFire 1.0 Certification Program is a significant milestone for the Alliance and represents the diligent efforts of our Certification Working Group to bring this program to the industry,” said Mazen Chmaytelli, president, MFA. “We are also excited to share that we have already certified the first MulteFire radio and device solutions from Nokia as compliant.”
“By enabling private wireless connectivity in unlicensed and shared spectrum, we enable even more enterprises to deploy their own private LTE and 5G networks,” said Stephan Litjens, General Manager, Nokia Digital Automation Cloud and MFA board chair. “As a founding member of MFA, we’re firmly at the forefront of this initiative – firstly with certification of our own MulteFire CPE offering – and also to accelerate a device ecosystem for the benefit of enterprise digital transformation.”
Through overlapping membership with 3GPP, the MFA is also supporting efforts for 5G NR standalone operation in unlicensed spectrum. A recent ABI Research white paper quantifies the total addressable market size for private network equipment (for industrial manufacturing, ports, logistics, mining, and energy) in LTE and 5G at $32.37B by 2030. ABI also states that by 2030 more than half of industry verticals’ private networks using LTE or 5G will be deployed in unlicensed, shared or dedicated licensed spectrum.
DEKRA Named Authorized Test Lab for MulteFire 1.0
DEKRA , an MFA member and leader in product certification, conducted the certification testing for MulteFire 1.0 and DEKRA Malaga has been named an Authorized Test Lab for the MulteFire 1.0 Certification Program. DEKRA was already named the first Authorized Test Lab for the MulteFire 1.9 GHz sXGP Certification Program launched in Japan at the end of 2019.
“DEKRA is very pleased to continue its partnership with the MFA with the addition of MulteFire 1.0 testing to our services offering, and we are happy to contribute to the success of the MulteFire ecosystem,” said Andrés Moreno, Managing Director, DEKRA Testing and Certification Spain.
The MFA Certification Program is available to all MFA members. Upon device certification, companies will receive the ‘MulteFire Certified’ logo and certification mark for product promotion and marketing purposes. The MFA welcomes membership from all companies that have an interest in private wireless networks. To join the MFA and for more details on membership levels, visit www.multefire.org/join .
For more information on the MFA Certification Program, visit www.multefire.org/certification-program/ .
Resources:
- ABI Research White Paper: The Importance of Spectrum Liberalization for Private 5G Networks
- Blog: MulteFire 1.0 Regulatory Analysis White Paper Now Available to MFA Members
- Webpage: Certification FAQ
About the MFA
The MFA is an international association dedicated to building a global ecosystem in support of the common interests of members, developers and users in the application of Long Term Evolution (LTE) and next-generation mobile cellular technology, such as 5G New Radio, in configurations that use unlicensed or shared radio spectrum. For more information about MulteFire technology, its benefits, or how to become a member of the MFA, visit www.MulteFire.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005382/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
